Physician profile

Randall Sarte

Foot & Ankle Surgery · Sacramento, CA

NPI 1760483085

$1,279.23

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

See the full distribution for Foot & Ankle Surgery

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$418.25
Debt Forgiveness$25.83

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Stryker Corporation $480.95 2019-2024 Actishield
Smith+Nephew, INC. $149.38 2023 Cadence
Integra Lifesciences Corporation $135.51 2019
Medtronic Vascular, INC. $132.26 2019
Orthofix Medical, INC. $115.56 2022
Next Science LLC $112.36 2022
Alafair Biosciences, INC. $94.96 2024 Versawrap
Sequoia Surgical, INC. $32.42 2020
Djo, LLC $25.83 2024

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Randall Sarte

$1,279.23

in general payments reported 2019-2025

Years
2019-2024
Top company
Stryker Corporation

https://glasscript.com/doctor/584149/randall-sarte

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.